Clearside Biomedical Changes Fiscal Year End

TL;DR

Clearside Biomedical (CLSD) is changing its fiscal year end to Dec 31, effective Sept 10, 2025.

AI Summary

Clearside Biomedical, Inc. filed an 8-K on September 11, 2025, reporting a change in its fiscal year end to December 31. This filing also includes financial statements and exhibits, with the earliest event reported being September 10, 2025. The company is incorporated in Delaware and headquartered in Alpharetta, Georgia.

Why It Matters

A change in fiscal year end can impact reporting schedules and financial comparisons for investors. This filing provides clarity on Clearside Biomedical's updated financial calendar.

Risk Assessment

Risk Level: low — This filing is a routine administrative update regarding the company's fiscal year end and does not involve significant operational or financial changes.

Key Numbers

• 1231 — New Fiscal Year End (The company has updated its fiscal year end to December 31.)

Key Players & Entities

• Clearside Biomedical, Inc. (company) — Registrant
• September 10, 2025 (date) — Date of earliest event reported
• September 11, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of Incorporation
• Alpharetta, Georgia (location) — Principal Executive Offices
• December 31 (date) — New Fiscal Year End

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar

Filing Documents

• clsd-20250910.htm (8-K) — 51KB
• clsd-ex3_1.htm (EX-3.1) — 26KB
• 0000950170-25-114089.txt ( ) — 188KB
• clsd-20250910.xsd (EX-101.SCH) — 25KB
• clsd-20250910_htm.xml (XML) — 5KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 10, 2025, Clearside Biomedical, Inc. (the " Company ") filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the " Amendment ") with the Secretary of State of the State of Delaware to effect a one-for-fifteen (1-for-15) reverse stock split (the " Reverse Stock Split ") of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 400,000,000 to 26,666,666 (the " Shares Reduction "). The Amendment will be effective at 5:00 p.m. Eastern Time on September 12, 2025. A series of alternate amendments to effect (i) a reverse stock split and (ii) a reduction in the total number of authorized shares of the Company's common stock was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on August 29, 2025, and the specific one-for-fifteen (1-for-15) Reverse Stock Split and corresponding Shares Reduction was subsequently approved by the Company's board of directors on September 4, 2025. The Amendment provides that, at the effective time of the Amendment, every fifteen (15) shares of the Company's issued and outstanding common stock will automatically be combined into one (1) issued and outstanding share of common stock and the authorized shares of the Company's common stock will be reduced from 400,000,000 to 26,666,666, without any change in par value per share. The Reverse Stock Split will affect all shares of the Company's common stock outstanding immediately prior to the effective time of the Amendment. As a result of the Reverse Stock Split, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options issued by the Company and outstanding immediately prior to the effective time of the Amendment, which will result in a proportionate decrease in the numb

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 11, 2025 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR